| Literature DB >> 32340217 |
Kouadio Ibrahime Sinan1, Gokhan Zengin1, Dimitrina Zheleva-Dimitrova2, Ouattara Katinan Etienne3, Mohamad Fawzi Mahomoodally4,5, Abdelhakim Bouyahya6, Devina Lobine5, Annalisa Chiavaroli7, Claudio Ferrante7, Luigi Menghini7, Lucia Recinella7, Luigi Brunetti7, Sheila Leone7, Giustino Orlando7.
Abstract
Achyranthes aspera Linn. (Amaranthaceae), commonly known as the Prickly Chaff flower, is used as herbal medicine in the Ivorian's culture, Africa. Nonetheless, there is currently a paucity of scientific information on A. aspera from the Ivory Coast. Herein, the antioxidant activity of A. aspera extracts (methanol, dichloromethane, ethyl acetate and infusion) as well as the enzymatic inhibitory potentials towards key enzymes in human diseases, namely Alzheimer's disease, (cholinesterases: AchE and BChE), type 2 diabetes (α-glucosidase and α-amylase) and hyperpigmentation (tyrosinase) were assessed. The total phenolic (TPC) and flavonoid (TFC) content was determined using colorimetric methods and the individual compounds were characterized using ultra-high performance liquid chromatography coupled with hybrid quadrupole-Orbitrap high resolution mass spectrometry (UHPLC-HRMS). Furthermore, a network pharmacology analysis was conducted to predict putative targets of identified phenolic compounds. The highest TPC was observed in the infused extract (28.86 ± 0.12 mg GAE/g), while the dichloromethane extract (38.48 ± 1.48 mg RE/g) showed the highest level of TFC. UHPLC-HRMS analysis has revealed an abundance of fatty acids, flavonoids, phenols and acylquinic acids. Among tested extracts, the infused extract displayed the highest free radical quenching, reducing and metal-chelating ability. The extracts (except infusion) were effective as enzyme inhibitors against AChE, while only methanolic and infused extracts showed noteworthy anti-BChE effects. The methanolic extract showed a remarkable antityrosinase effect (56.24 ± 5.05 mg KAE/g), as well. Modest to moderate inhibitory activity was observed against α-amylase (all extracts) and α-glucosidase (only dichloromethane extract). Finally, the network pharmacology analysis suggested the carbonic anhydrase II enzyme as a putative target for explaining, at least in part, the traditional use of A. aspera preparations as diuretic and blood clotting agent. Data amassed herein tend to validate the use of A. aspera in traditional medicine, as well as act as a stepping stone for further studies in the quest for novel phytopharmaceuticals. In this context, it is desirable that this study will contribute to the validation of the traditional uses of this plant in the African herbal medicine, and to the valorization of the whole chain production of A. aspera, as a local and sustainable botanical resource.Entities:
Keywords: Achyranthes aspera; antioxidant; enzyme inhibition; fatty acids; network pharmacology; phytopharmaceutics
Year: 2020 PMID: 32340217 PMCID: PMC7221715 DOI: 10.3390/molecules25081973
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Total phenolic (TPC), flavonoid (TFC) content and radical scavenging abilities (1,1-diphenyl-2-picrylhydrazyl (DPPH·) radical and 2,2-azino-bis (3-ethylbenzothiazloine-6-sulfonic acid) radical cation (ABTS+) of the tested extracts. Values expressed are means ± S.D. of three parallel measurements. GAE: Gallic acid equivalent; RE: Rutin equivalent. TE: Trolox equivalent. Based on Tukey’s assay at p < 0.05, different letters (a, b, c and d) with in each bar indicated significant differences among the tested extracts (a: the highest value).
Peak assessment of metabolites in Achyranthes aspera extracts.
| No | Tentative Structure | Molecular Formula | Exact Mass [M − H]− | Presence | Reference | |
|---|---|---|---|---|---|---|
| Fatty acids | ||||||
| 1 | azelaic acid | C9H16O4 | 187.0968 | 1,2,4 | [ | |
| 2 | undecanedioic acid | C11H20O4 | 215.1285 | 1,2,3 | ||
| 3 | dodecenedioic acid (traumatic acid) | C12H20O4 | 227.1289 | 1,2,3,4 | ||
| 4 | dodecanoic acid (lauric acid) | C12H22O4 | 229.1442 | 1,2,3,4 | ||
| 5 | linolenic acid | C18H30O2 | 277.2177 | 1 | [ | |
| 6 | 8-hydroxy-9,11,13-heptadecatrienoc acid | C17H28O3 | 279.1968 | 1,3 | ||
| 7 | 12-hydroxy-6-heptadecenoic acid | C17H30O3 | 281.2123 | 1,3 | ||
| 8 | 9-hydroxy-10,11,13,15-octadecatetranoic acid | C18H28O3 | 291.1970 | 1,3 | ||
| 9 | 13-hydroxy-9,11,15-octadecatrienoic acid | C18H30O3 | 293.2119 | 1,2,3,4 | ||
| 10 | 15-hydroxy-9,11,13-octadecatrienoic acid | C18H30O3 | 293.2126 | 1,2,3,4 | ||
| 11 | 13-hydroxy-9,11-octadecadienoic acid | C18H32O3 | 295.2280 | 1,2,3,4 | [ | |
| 12 | 9-hydroxy-?-octadecenoic acid | C18H34O3 | 297.2438 | 1,3 | [ | |
| 13 | 15-hydroxy-9-oxo-10,12,14-octadecatrienoic acid | C18H26O4 | 305.1762 | 1,2,3,4 | ||
| 14 | 14-hydroxy-9-oxo-11,13,15-octadecatrienoic acid | C18H28O4 | 307.1919 | 1,2,3,4 | ||
| 15 | 9,10-dihydroxy-12,14,16-octadecatrienoic acid | C18H30O4 | 309.2076 | 1,2,3,4 | ||
| 16 | 9,10-dihydroxy-11,13,16-octadecatrienoic acid | C18H30O4 | 309.2074 | 1,2,3 | ||
| 17 | 9,10-dihydroxy-12,15,16-octadecatrienoic acid | C18H30O4 | 309.2074 | 1,2,3,4 | ||
| 18 | 11,12-dihydroxy-9,14,15-octadecatrienoic acid | C18H30O4 | 309.2076 | 1,2,3,4 | ||
| 19 | 15,16-dihydroxy-9,12-octadecadienoic acid | C18H32O4 | 311.2234 | 1,3,4 | ||
| 20 | 9,10-dihydroxy-12,14-octadecadienoic acid | C18H32O4 | 311.2233 | 1,2,3,4 | ||
| 21 | 9,10-dihydroxy-10,13-octadecadienoic acid | C18H32O4 | 311.2232 | 1,2,3,4 | ||
| 22 | 12,13-dihydroxy-9-octadecenoic acid | C18H34O4 | 313.2389 | 1,2,3,4 | [ | |
| 23 | 9,10-dihydroxy-12-octadecenoic acid | C18H34O4 | 313.2388 | 1,2,3,4 | [ | |
| 24 | 9,10-dihydroxy-octadecanoic acid | C18H36O4 | 315.2544 | 1,2,3 | [ | |
| 25 | 9,10,13-trihydroxy-11,15-octadecadienoic acid | C18H32O5 | 327.2179 | 1,2,3,4 | ||
| 26 | 9,12,13-trihydroxy-10,15-octadecadienoic acid | C18H32O5 | 327.2179 | 1,2,3,4 | ||
| 27 | 11,12,15-trihydroxy-9,12-octadecadienoic acid | C18H32O5 | 327.2179 | 1,2,3,4 | ||
| 28 | 11,12,13-trihydroxy-9,12-octadecadienoic acid | C18H32O5 | 327.2179 | 1,2,3,4 | ||
| 29 | 9,10,15-trihydroxy-12,15-octadecadienoic acid | C18H32O5 | 327.2179 | 1,2,3,4 | ||
| 30 | 11,12,15-trihydroxy-9,12-octadecadienoic acid | C18H32O5 | 327.2180 | 1,2,3,4 | ||
| 31 | 9,10,13-trihydroxy,12-octadecenoic acid | C18H34O5 | 329.2338 | 1,2,3,4 | [ | |
| 32 | 9,12,13-trihydroxy,10-octadecenoic acid | C18H34O5 | 329.2338 | 1,2,3,4 | [ | |
| Carboxylic, phenolic and acylquinic acids, and phenylethanoid glycosides | ||||||
| 33 | salicylic acid | C7H6O3 | 137.0230 | 1,2,3,4 | ||
| 34 | protocatechuic acid | C7H6O4 | 153.0184 | 1,2,3 | * | |
| 35 | gentisic acid | C7H6O4 | 153.0183 | 2,3,4 | * | |
| 36 | caffeic acid | C9H8O4 | 179.0338 | 1,2,3,4 | * | |
| 37 | quinic acid | C7H12O6 | 191.0552 | 1,2,3,4 | ||
| 38 | ferulic acid | C10H10O4 | 193.0498 | 1,2,3,4 | * | |
| 39 | salicylic acid- | C13H16O8 | 299.0776 | 1,2,3,4 | ||
| 40 | gentisic acid- | C13H16O9 | 315.0725 | 2,4 | ||
| 41 | chlorogenic (5-caffeoylquinic) acid | C16H18O9 | 353.0867 | 1,2,3,4 | * | |
| 42 | 4-caffeoylquinic acid | C16H18O9 | 353.0872 | 3,4 | ||
| 43 | 3,5-dicaffeoylquinic acid | C25H24O12 | 515.1218 | 1,2,3,4 | * | |
| 44 | 4,5-dicaffeoylquinic acid | C25H24O12 | 515.1198 | 1,2,3,4 | * | |
| 45 | 3,4,5-tricaffeoylquinic acid | C34H30O15 | 677.1532 | 1,2,3 | * | |
| Flavonoids | ||||||
| 46 | kaempferol-3- | C21H20O11 | 447.0941 | 1,2,3,4 | * | |
| 47 | isoquercitrin | C21H20O12 | 463.0891 | 1,2,3,4 | * | |
| 48 | apigenin-7- | C27H28O15 | 591.1356 | 1,2,3,4 | ||
| 49 | kaempferol-3- | C27H30O15 | 593.1522 | 1,2,3,4 | ||
| 50 | kaempferol-3- | C27H30O15 | 593.1528 | 1,2,3,4 | * | |
| 51 | tiliroside | C30H26O13 | 593.1307 | 1,2,4 | * | |
| Other compounds | ||||||
| 52 | Roseoside corchoionoside C | C19H30O8 | 385.1884 | 1,2,3,4 | ||
| 53 | rubrosterone | C19H26O5 | 333.1680 | 1,2,3,4 | ||
| 54 | 20-hydroxyecdysterone | C27H44O7 | 479.3018 | 1,2,3,4 | [ | |
*—compared to reference standard. 1—ethyl acetate, 2—methanol, 3—DCM and 4—infusion.
Enzyme inhibitory properties of the tested extracts *.
| AChE Inhibition | BChE Inhibition | Tyrosinase Inhibition | α-Amylase Inhibition | α-Glucosidase Inhibition | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| mg GALAE/g | IC50 (mg /mL) | mg GALAE/g | IC50 (mg /mL) | Mg KAE/g | IC50 (mg /mL) | mmol ACAE/g | IC50 (mg /mL) | mmol ACAE/g | IC50 (mg /mL) | ||
| Extracts | DCM | 3.97 ± 0.36 b | 0.68 ± 0.02 b | na | na | na | na | 0.66 ± 0.03 a | 1.69 ± 0.08 b | 2.28 ± 0.17 | 0.80 ± 0.06 a |
| EA | 3.28 ± 0.21 c | 0.82 ± 0.05 c | na | na | na | na | 0.68 ± 0.01 a | 1.65 ± 0.01 b | na | na | |
| Infusion | na | na | 15.36 ± 0.22 a | 0.55 ± 0.01 b | na | na | 0.20 ± 0.01 b | >5 | na | na | |
| MeOH | 4.87 ± 0.10 a | 0.55 ± 0.01 b | 16.00 ± 0.48 a | 0.53 ± 0.01 b | 56.24 ± 5.05 | 1.90 ± 0.17 b | 0.63 ± 0.04 a | 1.78 ± 0.12 b | na | na | |
| Standards | Galatamine | 0.003 ± 0.0001 a | 0.008 ± 0.0001 a | − | − | − | |||||
| Kojic acid | − | − | 0.11 ± 0.01 a | − | − | ||||||
| Acarbose | − | − | − | 0.72 ± 0.02 a | 1.04 ± 0.08 b | ||||||
* Values expressed are means ± S.D. of three parallel measurements. GALAE: Galatamine equivalent; KAE: Kojic acid equivalent; ACAE: Acarbose equivalent. Based on Tukey’s assay at p < 0.05, different letters (a, b, c and d) with same column indicated significant differences among the tested extracts (a: the highest ability). na: not active. − not tested.
Figure 2Reducing power (CUPRAC and FRAP), metal-chelating and phosphomolybdenum activities of the tested extracts. Values expressed are means ± S.D. of three parallel measurements. TE: Trolox equivalent; EDTAE: EDTA equivalent. Based on Tukey’s assay at p < 0.05, different letters (a, b, c and d) with in each bar indicated significant differences among the tested extracts (a: the highest value).
Figure 3Unsupervised multivariate analysis with principal component analysis on A. aspera biological activities.
Figure 4Pharmacological profile of phenolic compounds identified through ultra-high performance liquid chromatography coupled with hybrid quadrupole-Orbitrap high resolution mass spectrometry (UHPLC-HRMS) analysis in methanol, ethylacetate and dichloromethane extracts, and in water infusion of A. aspera dried aerial parts. Molecular target and pharmacokinetic profile were predicted through SwissTargetPrediction (http://www.swisstargetprediction.ch/) and SwissADME (http://www.swissadme.ch/index.php) platforms, respectively. Accordingly, the Venn diagram (A) was conducted based on high gastrointestinal absorption, blood barrier permeation and high probability to interact with a selected molecular target (carbonic anhydrase II). Finally, based on Venn diagram, components-targets analysis (B) was carried out through Cytoscape software (3.7.2 version) on apigenin, ferulic acid and salicylic acid. Extended results are included as Supplementary Materials (Supplementary Material Bioinformatic Analysis). A. Venn diagram related to selected phenolic compounds; B. Components-targets analysis. Single predicted carbonic anhydrase targets.